The risks for endometrial carcinoma development by age 75 were found to be up to 37.0%, 48.9%, 41.1%, and 12.8% for MLH1, MSH2, MSH6 and PMS2 carriers, respectively. This evidence concerns the gene MLH1 and endometrial carcinoma.